Arcus Biosciences Prices $250 Million Common Stock Offering

Arcus Biosciences, Inc. has priced an underwritten public offering of its common stock, targeting gross proceeds of $250 million. The company, which specializes in developing cancer therapies, is engaged in a significant capital-raising effort. This announcement was made on October 22, 2026.